NCT02249403View on ClinicalTrials.gov

Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type

PHASE2CompletedINTERVENTIONAL
Enrollment

362

Participants

Timeline

Start Date

January 31, 1999

Primary Completion Date

January 31, 2000

Conditions
Alzheimer Disease
Interventions
DRUG

Talsaclidine 6 mg

DRUG

Talsaclidine 12 mg

DRUG

Talsaclidine 24 mg

DRUG

Talsaclidine 36 mg

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY